Skip to main content

Liposomal Bupivacaine Analgesia in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Retrospective Cohort Study.

Publication ,  Journal Article
Knackstedt, RW; Lin, JH; Kakoty, S
Published in: Plast Reconstr Surg Glob Open
June 2024

BACKGROUND: Liposomal bupivacaine (LB) can be used for postsurgical analgesia after breast reconstruction. We examined real-world clinical and economic benefits of LB versus bupivacaine after deep inferior epigastric perforator (DIEP) flap breast reconstruction. METHODS: This retrospective cohort study used the IQVIA claims databases to identify patients undergoing primary DIEP flap breast reconstruction in 2016-2019. Patients receiving LB and those receiving bupivacaine were compared to assess opioid utilization in morphine milligram equivalents (MMEs) and healthcare resource utilization during perioperative (2 weeks before surgery to 2 weeks after discharge) and 6-month postdischarge periods. A generalized linear mixed-effects model and inverse probability of treatment weighting method were performed. RESULTS: Weighted baseline characteristics were similar between cohorts (LB, n = 669; bupivacaine, n = 348). The LB cohort received significantly fewer mean MMEs versus the bupivacaine cohort during the perioperative (395 versus 512 MMEs; rate ratio [RR], 0.771 [95% confidence interval (CI), 0.677-0.879]; P = 0.0001), 72 hours after surgery (63 versus 140 MMEs; RR, 0.449 [95% CI, 0.347-0.581]; P < 0.0001), and inpatient (154 versus 303 MMEs; RR, 0.508 [95% CI, 0.411-0.629]; P < 0.0001) periods; postdischarge filled opioid prescriptions were comparable. The LB cohort was less likely to have all-cause inpatient readmission (odds ratio, 0.670 [95% CI, 0.452-0.993]; P = 0.046) and outpatient clinic/office visits (odds ratio, 0.885 [95% CI, 0.785-0.999]; P = 0.048) 3 months after discharge than the bupivacaine cohort; other all-cause healthcare resource utilization outcomes were not different. CONCLUSIONS: LB was associated with fewer perioperative MMEs and all-cause 3-month inpatient readmissions and outpatient clinic/office visits than bupivacaine in patients undergoing DIEP flap breast reconstruction.

Duke Scholars

Published In

Plast Reconstr Surg Glob Open

DOI

ISSN

2169-7574

Publication Date

June 2024

Volume

12

Issue

6

Start / End Page

e5874

Location

United States

Related Subject Headings

  • 3213 Paediatrics
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Knackstedt, R. W., Lin, J. H., & Kakoty, S. (2024). Liposomal Bupivacaine Analgesia in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Retrospective Cohort Study. Plast Reconstr Surg Glob Open, 12(6), e5874. https://doi.org/10.1097/GOX.0000000000005874
Knackstedt, Rebecca W., Jennifer H. Lin, and Swapnabir Kakoty. “Liposomal Bupivacaine Analgesia in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Retrospective Cohort Study.Plast Reconstr Surg Glob Open 12, no. 6 (June 2024): e5874. https://doi.org/10.1097/GOX.0000000000005874.
Knackstedt RW, Lin JH, Kakoty S. Liposomal Bupivacaine Analgesia in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Retrospective Cohort Study. Plast Reconstr Surg Glob Open. 2024 Jun;12(6):e5874.
Knackstedt, Rebecca W., et al. “Liposomal Bupivacaine Analgesia in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Retrospective Cohort Study.Plast Reconstr Surg Glob Open, vol. 12, no. 6, June 2024, p. e5874. Pubmed, doi:10.1097/GOX.0000000000005874.
Knackstedt RW, Lin JH, Kakoty S. Liposomal Bupivacaine Analgesia in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Retrospective Cohort Study. Plast Reconstr Surg Glob Open. 2024 Jun;12(6):e5874.

Published In

Plast Reconstr Surg Glob Open

DOI

ISSN

2169-7574

Publication Date

June 2024

Volume

12

Issue

6

Start / End Page

e5874

Location

United States

Related Subject Headings

  • 3213 Paediatrics
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences